GlobalRPH - Prostate News

Medical News

< back to feeds
Prostate News
Multidisciplinary Meeting On Urological Cancers Experts agree that the urological cancer patient will benefit greatly if the delivered treatment is the result of a combined effort. Collaboration of experts from various fields is, therefore, necessary to take cancer-related research and medical practice to the next level. ...more	20 Nov 2009
Tulane Cancer Center To Begin Novel Clinical Trial For Late-Stage Prostate Cancer Drug International prostate cancer expert Dr. Oliver Sartor of Tulane Cancer Center is the first oncologist in the United States to offer patients an experimental new treatment for late-stage prostate cancer through a multi-center clinical trial that is currently recruiting patients at 100 sites across 20 countries worldwide. ...more	18 Nov 2009
Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies Of Apoptone (HE3235) At AACR Molecular Targets Conference Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH), reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone® (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC). ...more	17 Nov 2009
Percentage Of Positive Biopsy Cores At The Onset Of Hormone Therapy For Prostate Cancer: Prognostic Significance UroToday.com - Accurate prediction of outcome after hormonal treatment for localized prostate cancer is important for patient counselling, follow-up, treatment planning and research protocol design. Few prognostic tools incorporating pre-therapeutic parameters are available to increase disease relapse predictions and survival. ...more	16 Nov 2009
Degarelix: A New Approach For The Treatment Of Prostate Cancer UroToday.com - Gonadotrophin-releasing hormone (GnRH) agonists are currently the 'standard of care' for androgen deprivation therapy (ADT) in prostate cancer. Improvements in ADT would have a great value for many patients. The agonists are associated with an initial testosterone surge, which delays castration and may stimulate tumor growth and induce 'clinical flare' in patients with symptomatic advanced disease. ...more	16 Nov 2009
Scientific Presentations At 2009 ASTRO Meeting Highlight RapidArc(R) Radiotherapy Technology From Varian Medical Systems Clinicians using RapidArc® radiotherapy technology for fast, precise, non-invasive cancer treatments have found that they are able to substantially reduce scatter dose to surrounding healthy tissues, according to several presentations and posters presented this week at the annual meeting of the American Society for Radiation Oncology (ASTRO) in Chicago. ...more	13 Nov 2009
Tokai Pharmaceuticals Initiates ARMOR Clinical Development Program For TOK-001; First Ever Multi-Target Investigational Drug For Prostate Cancer Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, announced the initiation of a Phase 1/2 clinical trial of its lead candidate TOK-001 for the treatment of patients with castration resistant prostate cancer (CRPC). TOK-001 is the only compound in development that combines three distinct mechanisms of action for the treatment of CRPC. ...more	12 Nov 2009
Routine Evaluation Of Prostate Size Not As Effective In Cancer Screening, Mayo Study Finds New Mayo Clinic research studied the association between prostate-specific antigen (PSA) levels and prostate size and found that routine annual evaluation of prostate growth is not necessarily a predictor for the development of prostate cancer. However the study suggests that if a man's PSA level is rising quickly, a prostate biopsy is reasonable to determine if he has prostate cancer. ...more	11 Nov 2009
New Finding Suggests Prostate Biopsy Is Not Always Necessary Researchers at Wake Forest University School of Medicine and the University of Wisconsin-Madison have discovered that some elevated prostate-specific antigen (PSA) levels in men may be caused by a hormone normally occurring in the body, and are not necessarily a predictor of the need for a prostate biopsy. Elevated levels of PSA have traditionally been seen as a potential sign of prostate cancer, leading to the widespread use of PSA testing. ...more	10 Nov 2009
New Synthetic Molecules Trigger Immune Response To HIV And Prostate Cancer Researchers at Yale University have developed synthetic molecules capable of enhancing the body's immune response to HIV and HIV-infected cells, as well as to prostate cancer cells. Their findings, published online in the Journal of the American Chemical Society, could lead to novel therapeutic approaches for these diseases. ...more	10 Nov 2009
Does Prostate-specific Antigen Velocity Help In Early Detection Prostate Cancer? The November issue of European Urology, the official journal of the European Association of Urology, features an article focussing on prostate specific antigen (PSA) velocity and early cancer detection. It has been suggested that changes in PSA over time aid prostate cancer detection. It is argued that a rapidly rising PSA may indicate a greater risk of diagnosis of prostate cancer even if PSA levels are low. ...more	10 Nov 2009
New Study About Prostatitis In The Journal Of Urology Shows Increasing Evidence That Chronic Prostatitis Is A Muscle Tension Disorder In the November 2009 issue of the Journal of Urology, Stanford Medical School researcher Dr. Rodney Anderson and researchers at the National Center for Pelvic Pain Research, in a new study, demonstrated a high correlation between the location of painful trigger points inside the pelvic floor muscles of men with chronic prostatitis and the location in the body where they routinely complain of pain. ...more	10 Nov 2009
Cancer Recurrence May Be Prevented By Chemo-Radiation Before Prostate Removal Researchers in the Oregon Health & Science University Knight Cancer Institute and the Portland Veterans Affairs Medical Center have found a combination of radiation therapy and chemotherapy given before prostate removal is safe and may have the potential to reduce cancer recurrence and improve patient survival. Their findings were presented this week at the 51st annual meeting of the American Society of Therapeutic Radiology and Oncology in Chicago. ...more	05 Nov 2009
Men Urged To Seek Advice Due To Faulty Prostate Cancer Home Test Kits Men who have used 'Simplicity Health' or 'Fortel' home testing kits for prostate cancer screening during the past 12 months are being urged to contact their GP for advice. This follows recent notification to the Medicines and Healthcare products Regulatory Agency (MHRA) that the two kits from batch number 1012 are faulty and could give a false negative result. The 1000 defective devices shipped to the UK were sold through pharmacies and via the internet. ...more	05 Nov 2009
Study Of Race, Income And Prostate Cancer Outcome A patient's socioeconomic status (income, marital status and race) has absolutely no impact on his outcome following curative radiation therapy for the treatment of prostate cancer, according to a new study from Henry Ford Hospital in Detroit. "This study offers an extremely important message for all patients with prostate cancer who receive radiation therapy," says Benjamin Movsas, M.D. ...more	05 Nov 2009
Time Between Treatment And PSA Recurrence Predicts Death From Prostate Cancer Men whose prostate specific antigen (PSA) rise within 18 months of radiotherapy are more likely to develop spread and die of their disease, according to an international study led by Fox Chase Cancer Center radiation oncologist Mark K. Buyyounouski, M.D., M.S. and presented at the annual meeting of the American Society for Radiation Oncology (ASTRO). "PSA is the gold standard for following prostate cancer patients after they receive radiation or surgery. ...more	05 Nov 2009
Blood Vessels Might Predict Prostate Cancer Behavior A diagnosis of prostate cancer raises the question for patients and their physicians as to how the tumor will behave. Will it grow quickly and aggressively and require continuous treatment, or slowly, allowing therapy and its risks to be safely delayed? The answer may lie in the size and shape of the blood vessels that are visible within the cancer, according to research led by investigators at The Ohio State University Comprehensive Cancer Center-Arthur G. ...more	05 Nov 2009
Risk For High-Grade Prostate Cancer May Be Reduced By Low Cholesterol Men with lower cholesterol are less likely than those with higher levels to develop high-grade prostate cancer - an aggressive form of the disease with a poorer prognosis, according to results of a Johns Hopkins collaborative study. In a prospective study of more than 5,000 U.S. men, epidemiologists say they now have evidence that having lower levels of heart-clogging fat may cut a man's risk of this form of cancer by nearly 60 percent. ...more	04 Nov 2009
Answers And Some New Questions Concerning Cholesterol And Cancer A pair of studies in Cancer Epidemiology, Biomarkers & Prevention, lay to rest the decades-long concern that lower total cholesterol may lead to cancer, and in fact lower cholesterol may reduce the risk of high-grade prostate cancer. Demetrius Albanes, M.D., a senior investigator at the National Cancer Institute, said early studies suggested that low cholesterol could increase the risk of certain types of cancer. ...more	04 Nov 2009
Studies Negate Concerns That Low Cholesterol Leads To Some Cancers Two new studies from the US published this week negate concerns that have been around since early studies done decades ago suggested that low cholesterol leads to some types of cancer: one in fact affirms that undiagnosed cancer is the likely cause of lower total cholesterol while the other found evidence linking low cholesterol and decreased risk of high-grade prostate cancer among older men. ...more	04 Nov 2009
Pages of Results: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 [Next] [Last Page]
Prostate News courtesy of Medical News Today	back to top

Medical News

Looking for a Job?

Career Center

Popular Tools

Disclaimer Contact Us Privacy Policy Website Search	We comply with the HONcode standard for health trustworthy information: Verify here. Copyright © 2007 GlobalRPh Inc.